Cargando…

1497. Cryptococcal Antigen Screening and Pre-emptive Fluconazole Therapy in HIV-infected Patients: A Multicenter, Retrospective Study in China

BACKGROUND: The implementation and effectivention of CrAg screening programs and pre-emptive treatment remains unclear in China. METHODS: We performed a multicenter, retrospective study at eight hospitals from 1st Jan 2019 to 31st Dec 2020, to evaluate whether CrAg screening programs and preemptive...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Yanqiu, Chen, Yaokai
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677837/
http://dx.doi.org/10.1093/ofid/ofad500.1332
_version_ 1785150224216358912
author Lu, Yanqiu
Chen, Yaokai
author_facet Lu, Yanqiu
Chen, Yaokai
author_sort Lu, Yanqiu
collection PubMed
description BACKGROUND: The implementation and effectivention of CrAg screening programs and pre-emptive treatment remains unclear in China. METHODS: We performed a multicenter, retrospective study at eight hospitals from 1st Jan 2019 to 31st Dec 2020, to evaluate whether CrAg screening programs and preemptive treatment are beneficial for saving lives in China. RESULTS: A total of 12768 PLWH were screened for serum CrAg. The prevalence of serum CrAg positivity was 5.3% (678/12768). Lumbar puncture (LP) records were completed and available in 580 patients. Among them, 36.4% (369/580) were diagnosed with CM, and 63.6% (211/580) were diagnosed with isolated cryptococcal antigenemia (ICA). 123 HIV/ICA patients have available clinical data. Of these patients, a median CD4(+) T-cell counts were 41cells/µL (IQR, 19-83). Upon Cox proportional-hazards regression analysis, patients with no preemptive fluconazole treatment had a threefold higher risk of CM and/or death [19.0% (8/42) vs 8.6% (7/81), p=0.037] compared to the preemptive fluconazole treatment participants. However, there was no statistically significant difference for the development of CM and/or death in different dosage (therapy as per WHO recommendations vs oral fluconazole 400mg daily therapy) of fluconazole therapy (p=0.836). Also, we found no statistically significant difference in the proportion of CrAg negativity [60.0% (12/20) vs 54.5% (18/33), p=0.779] and the median time from positivity to negativity of serum CrAg [14 (IOR:9.25, 14) vs 14 (10.5, 15), p=1.000] within one year follow up. In our study, Patients who with virological suppression had a lower incidence of CM and/or death than patients who with virological non-suppression [5.6% (1/18) vs (17.2% (5/29), p=0.384], however, there was no statistically significant difference in Cox proportional-hazards regression analysis. [Figure: see text] [Figure: see text] [Figure: see text] CONCLUSION: Rapid ART initiation, appropriate CrAg screening are essential for advanced PLWH. Lp is a necessary intervention in advanced HIV-infected patients for CrAg positive individual to prevent potential missed diagnosis and mistreatment of CM. Targeted improvements to pre-emptive antifungal therapy for cryptococcal antigenemia are required to further improve patient outcomes in CrAg-positive severely immunocompromised people with HIV/AIDS. DISCLOSURES: All Authors: No reported disclosures
format Online
Article
Text
id pubmed-10677837
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-106778372023-11-27 1497. Cryptococcal Antigen Screening and Pre-emptive Fluconazole Therapy in HIV-infected Patients: A Multicenter, Retrospective Study in China Lu, Yanqiu Chen, Yaokai Open Forum Infect Dis Abstract BACKGROUND: The implementation and effectivention of CrAg screening programs and pre-emptive treatment remains unclear in China. METHODS: We performed a multicenter, retrospective study at eight hospitals from 1st Jan 2019 to 31st Dec 2020, to evaluate whether CrAg screening programs and preemptive treatment are beneficial for saving lives in China. RESULTS: A total of 12768 PLWH were screened for serum CrAg. The prevalence of serum CrAg positivity was 5.3% (678/12768). Lumbar puncture (LP) records were completed and available in 580 patients. Among them, 36.4% (369/580) were diagnosed with CM, and 63.6% (211/580) were diagnosed with isolated cryptococcal antigenemia (ICA). 123 HIV/ICA patients have available clinical data. Of these patients, a median CD4(+) T-cell counts were 41cells/µL (IQR, 19-83). Upon Cox proportional-hazards regression analysis, patients with no preemptive fluconazole treatment had a threefold higher risk of CM and/or death [19.0% (8/42) vs 8.6% (7/81), p=0.037] compared to the preemptive fluconazole treatment participants. However, there was no statistically significant difference for the development of CM and/or death in different dosage (therapy as per WHO recommendations vs oral fluconazole 400mg daily therapy) of fluconazole therapy (p=0.836). Also, we found no statistically significant difference in the proportion of CrAg negativity [60.0% (12/20) vs 54.5% (18/33), p=0.779] and the median time from positivity to negativity of serum CrAg [14 (IOR:9.25, 14) vs 14 (10.5, 15), p=1.000] within one year follow up. In our study, Patients who with virological suppression had a lower incidence of CM and/or death than patients who with virological non-suppression [5.6% (1/18) vs (17.2% (5/29), p=0.384], however, there was no statistically significant difference in Cox proportional-hazards regression analysis. [Figure: see text] [Figure: see text] [Figure: see text] CONCLUSION: Rapid ART initiation, appropriate CrAg screening are essential for advanced PLWH. Lp is a necessary intervention in advanced HIV-infected patients for CrAg positive individual to prevent potential missed diagnosis and mistreatment of CM. Targeted improvements to pre-emptive antifungal therapy for cryptococcal antigenemia are required to further improve patient outcomes in CrAg-positive severely immunocompromised people with HIV/AIDS. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2023-11-27 /pmc/articles/PMC10677837/ http://dx.doi.org/10.1093/ofid/ofad500.1332 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Abstract
Lu, Yanqiu
Chen, Yaokai
1497. Cryptococcal Antigen Screening and Pre-emptive Fluconazole Therapy in HIV-infected Patients: A Multicenter, Retrospective Study in China
title 1497. Cryptococcal Antigen Screening and Pre-emptive Fluconazole Therapy in HIV-infected Patients: A Multicenter, Retrospective Study in China
title_full 1497. Cryptococcal Antigen Screening and Pre-emptive Fluconazole Therapy in HIV-infected Patients: A Multicenter, Retrospective Study in China
title_fullStr 1497. Cryptococcal Antigen Screening and Pre-emptive Fluconazole Therapy in HIV-infected Patients: A Multicenter, Retrospective Study in China
title_full_unstemmed 1497. Cryptococcal Antigen Screening and Pre-emptive Fluconazole Therapy in HIV-infected Patients: A Multicenter, Retrospective Study in China
title_short 1497. Cryptococcal Antigen Screening and Pre-emptive Fluconazole Therapy in HIV-infected Patients: A Multicenter, Retrospective Study in China
title_sort 1497. cryptococcal antigen screening and pre-emptive fluconazole therapy in hiv-infected patients: a multicenter, retrospective study in china
topic Abstract
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10677837/
http://dx.doi.org/10.1093/ofid/ofad500.1332
work_keys_str_mv AT luyanqiu 1497cryptococcalantigenscreeningandpreemptivefluconazoletherapyinhivinfectedpatientsamulticenterretrospectivestudyinchina
AT chenyaokai 1497cryptococcalantigenscreeningandpreemptivefluconazoletherapyinhivinfectedpatientsamulticenterretrospectivestudyinchina